CMMB Insider Trading
Insider Ownership Percentage: 11.91%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Chemomab Therapeutics Share Price & Price History
Current Price: $2.08
Price Change: ▼ Price Decrease of -0.04 (-1.89%)
As of 01/24/2025 05:00 PM ET
Chemomab Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/3/2023 | Israel Gp Ltd. Orbimed | Major Shareholder | Sell | 336,900 | $3.58 | $1,206,102.00 | 2,241,274 |  |
| 11/16/2022 | George Adi Mor | Insider | Sell | 324,775 | $2.08 | $675,532.00 | 324,775 | |
| 11/16/2022 | Neil Harris Cohen | Director | Sell | 2,409 | $2.00 | $4,818.00 | 10,000 | |
| 3/18/2022 | Joel Michael Maryles | Director | Buy | 1,000 | $4.34 | $4,340.00 | | |
| 3/16/2022 | Donald Marvin | CFO | Buy | 500 | $3.27 | $1,635.00 | 2,000 | |
| 3/14/2022 | Dale R Pfost | CEO | Buy | 2,500 | $3.98 | $9,950.00 | | |
| 3/14/2022 | Donald Marvin | CFO | Buy | 1,250 | $4.04 | $5,050.00 | | |
| 3/14/2022 | Neil Harris Cohen | Director | Buy | 6,000 | $4.35 | $26,100.00 | | |
Chemomab Therapeutics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 11/15/2024 | Sphera Funds Management LTD. | 1,214,575 | $1.91M | 0.3% | N/A | 8.458% |  |
| 2/1/2023 | Kestra Private Wealth Services LLC | 31,241 | $100K | 0.0% | N/A | 0.271% | |
| 2/14/2022 | GSA Capital Partners LLP | 11,277 | $78K | 0.0% | N/A | 0.099% | |
| 1/28/2022 | ARK Investment Management LLC | 267,292 | $1.84M | 0.0% | +48.1% | 2.344% | |
| 11/17/2021 | Yahav Achim Ve Achayot Provident Funds Management Co Ltd. | 3,097 | $34K | 0.0% | N/A | 0.027% | |
| 11/5/2021 | Advisor Group Holdings Inc. | 54,821 | $0.61M | 0.0% | N/A | 0.481% | |
| 11/3/2021 | Meitav Dash Investments Ltd. | 37,567 | $0.42M | 0.0% | -7.6% | 0.330% | |
| 9/17/2021 | Virtu Financial LLC | 13,180 | $0.25M | 0.0% | N/A | 0.116% | |
| 8/25/2021 | Marshall Wace LLP | 63,554 | $1.21M | 0.0% | N/A | 0.558% | |
| 8/25/2021 | Marshall Wace North America L.P. | 44,035 | $0.84M | 0.0% | N/A | 0.386% | |
| 8/18/2021 | Ikarian Capital LLC | 290,534 | $5.53M | 0.4% | N/A | 2.640% | |
| 8/18/2021 | Meitav Dash Investments Ltd. | 40,664 | $0.77M | 0.0% | +389.3% | 0.370% | |
| 8/17/2021 | Boothbay Fund Management LLC | 54,729 | $1.04M | 0.0% | -11.4% | 0.512% | |
| 8/16/2021 | Marshall Wace LLP | 63,554 | $1.21M | 0.0% | N/A | 0.594% | |
| 8/5/2021 | Meitav Dash Investments Ltd. | 40,664 | $0.77M | 0.0% | +389.3% | 0.380% | |
| 5/18/2021 | Orbimed Advisors LLC | 2,578,174 | $74.02M | 0.7% | N/A | 110.320% | |
| 5/13/2021 | Renaissance Technologies LLC | 7,023 | $0.20M | 0.0% | N/A | 0.301% | |
| 5/6/2021 | Meitav Dash Investments Ltd. | 8,311 | $0.24M | 0.0% | N/A | 0.356% | |
Data available starting January 2016
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Read More on Chemomab Therapeutics
Volume
54,814 shs
Average Volume
102,729 shs
Market Capitalization
$29.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.65
